ATRIAL FIBRILLATION IS ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS UNDERGOING TAVR: INSIGHTS FROM THE PARTNER TRIAL  by Biviano, Angelo et al.
TCT@ACC-i2: The Interventional Learning Pathway
A1686
JACC April 1, 2014
Volume 63, Issue 12
AtriAl fibrillAtion is AssociAteD With increAseD MortAlity in PAtients unDergoing tAVr: 
insights froM the PArtner triAl
Oral Contributions
Room 202 B
Saturday, March 29, 2014, 9:00 a.m.-9:10 a.m.
Session Title: Transcather Valve Therapies I
Abstract Category: 42. TCT@ACC-i2: Aortic Valve Disease
Presentation Number: 2901-07
Authors: Angelo Biviano, Jose Dizon, Tamim Nazif, Samir Kapadia, Vasilis Babaliaros, Ke Xu, Josep Rodes-Cabau, Wilson Szeto, William Fearon, 
Danny Dvir, Todd Dewey, Mathew Williams, Michael Mack, John Webb, D. Craig Miller, Craig Smith, Martin Leon, Susheel Kodali, Columbia 
University Medical Center/ New York Presbyterian Hospital, New York, NY, USA
background: Atrial fibrillation or flutter (AF) has been associated with worse clinical outcomes in many cardiovascular (CV) disease states, but 
there are scant data in patients undergoing transcatheter aortic valve replacement (TAVR).
Methods: Data were evaluated in 1879 patients with baseline and discharge ECGs who underwent TAVR in The PARTNER Trial. Clinical outcomes at 
30d and 1yr were compared in patients by heart rhythm [sinus rhythm (SR) vs. AF]. Subgroup analyses of AF patients based on ventricular response 
<90 bpm vs. ≥90 bpm and TAVR type (transfemoral vs. transapical) were also performed.
results: 1262 patients manifested SR at baseline/SR at discharge, 113 SR baseline/AF discharge, 34 AF baseline/SR discharge, and 470 AF 
baseline/AF discharge. Patients who converted from SR to AF by discharge had the highest rates of all-cause mortality at 30d (14.2% SR/AF vs 
2.6% SR/SR; p<0.0001) and 1yr (35.7% SR/AF vs 15.8% SR/SR; p<0.0001). CV mortality was also increased in the SR/AF conversion group at 30d 
(8.3% SR/AF vs 1.6% SR/SR; p<0.0001) and 1yr (20.6% SR/AF vs 9.0% SR/SR; p<0.0001). Compared to patients in SR at baseline and discharge, 
multivariable regression revealed that the presence of AF on baseline and/or discharge ECG was an independent predictor of increased 1yr all-cause 
mortality (HR 1.88, 95% CI 1.53-2.32, p<0.0001) and SR/AF conversion patients were at highest risk of all-cause mortality at 30d (HR 3.28, 95% 
CI 1.75-6.17, p=0.0002) and 1yr (HR 2.27, 95% CI 1.59-3.23, p<0.0001), as well as CV mortality at 30d (HR 2.92, 95% CI 1.26-6.75, p=0.0123) 
and 1yr (HR 2.19, 95% CI 1.35-3.57, p=0.0016). For patients discharged in AF, those with lower ventricular response (i.e. <90 bpm) experienced less 
1yr all-cause mortality (HR 0.74, 95% CI 0.55-0.99, p=0.04) and CV mortality (HR 0.55, 95% CI, 0.38-0.79, p=0.0014). There were no significant 
differences in mortality outcomes when accounting for TAVR type or development of stroke.
conclusions: After TAVR, the presence of AF at baseline and/or discharge, and particularly the conversion to AF by discharge and the presence of 
ventricular response >90 bpm at discharge, are associated with increased early and late all-cause and CV mortality.
